An antibody (called anti-CPP*) in the bloodstream of patients with rheumatoid arthritis correlates with their response to different drugs, according to a new study presented at the EULAR 2016 conference. Being positive for the antibody was associated with a better response to the T cell co-stimulation blocker abatacept, however, this antibody status was not correlated with the effectiveness of a tumour necrosis factor-inhibitor.

Click here for more.